The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The efficacy and feasibility of using radiotherapy as a bridge to CAR-T in patients with lymphoma
Andrea Kuhnl, MD, King’s College Hospital, London, UK, comments on the effectiveness and feasibility of radiotherapy as a bridge to CAR T-cell therapy for patients with lymphoma, highlighting its ability to debulk even advanced-stage disease. Dr Kuhnl notes that logistics and capacity likely present the main challenges, requiring improvement in expertise and infrastructure to expand access to this treatment approach. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Radiotherapy is a very effective treatment modality. Most CAR-T patients are chemorefractory and radiotherapy naive, so this is a very efficacious modality. And if we combine full dose and low dose radiotherapy, we’re really able to expand the field to effectively debulk even advanced stage patients. We’ve seen an uptake in radiotherapy bridging in the UK and have published our UK real world experience last year showing the very favorable outcomes of patients who were bridged with radiotherapy as a single modality...
Radiotherapy is a very effective treatment modality. Most CAR-T patients are chemorefractory and radiotherapy naive, so this is a very efficacious modality. And if we combine full dose and low dose radiotherapy, we’re really able to expand the field to effectively debulk even advanced stage patients. We’ve seen an uptake in radiotherapy bridging in the UK and have published our UK real world experience last year showing the very favorable outcomes of patients who were bridged with radiotherapy as a single modality. Now this will partly be a selection bias because we tend to choose radiotherapy bridging for lower-risk patients, but it might also indicate some synergistic or priming effects. Now the main challenge of using radiotherapy peri-CAR-T is really logistics and capacity so you need to deliver modern techniques in a very short turnaround so I think we need to continue to improve expertise and infrastructure across the region so that more and more patients can be treated in all larger network centres.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: Kite Gilead, Roche, Abbvie, BMS; Honoraria: Kite Gilead, Astra Zeneca.
